دورية أكاديمية
أعرض في EDS

Radiation Major Hepatectomy Using Ablative Dose Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma 5 cm or Larger.

التفاصيل البيبلوغرافية
العنوان: Radiation Major Hepatectomy Using Ablative Dose Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma 5 cm or Larger.
المؤلفون: Choi JW; Department of Radiology, Seoul National University Hospital, Seoul, Korea; Department of Radiology, Seoul National University College of Medicine, Seoul, Korea., Suh M; Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Korea., Paeng JC; Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Korea., Kim JH; Department of Radiology, Seoul National University Hospital, Seoul, Korea; Department of Radiology, Seoul National University College of Medicine, Seoul, Korea., Kim HC; Department of Radiology, Seoul National University Hospital, Seoul, Korea; Department of Radiology, Seoul National University College of Medicine, Seoul, Korea. Electronic address: radioembolization@snu.ac.kr.
المصدر: Journal of vascular and interventional radiology : JVIR [J Vasc Interv Radiol] 2024 Feb; Vol. 35 (2), pp. 203-212. Date of Electronic Publication: 2023 Oct 21.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Society of Cardiovascular and Interventional Radiology Country of Publication: United States NLM ID: 9203369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-7732 (Electronic) Linking ISSN: 10510443 NLM ISO Abbreviation: J Vasc Interv Radiol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Reston, Va. : Society of Cardiovascular and Interventional Radiology, c1990-
مواضيع طبية MeSH: Carcinoma, Hepatocellular*/diagnostic imaging , Carcinoma, Hepatocellular*/radiotherapy , Liver Neoplasms*/diagnostic imaging , Liver Neoplasms*/radiotherapy , Embolization, Therapeutic*/adverse effects, Humans ; Hepatectomy ; Retrospective Studies ; Yttrium Radioisotopes/adverse effects ; Microspheres ; Treatment Outcome
مستخلص: Purpose: To evaluate the safety and effectiveness of ablative radioembolization for large hepatocellular carcinoma (HCC) while preserving a small future liver remnant (FLR).
Materials and Methods: Twenty-five patients with large HCC of ≥5 cm requiring treatment for >60% of the total liver volume and having well-preserved liver function were treated with ablative glass microsphere radioembolization at a single institution from January 2017 to December 2021. Radioembolization was performed with a mean absorbed dose of >150 Gy, and the FLR per nontumor liver volume (NTLV) was set at >30%. Changes in liver function, adverse events, duration of response (DoR) in a treated area, time-to-progression (TTP), and overall survival (OS) were retrospectively investigated.
Results: The largest tumor diameter and planned dose per treated volume were 11.4 cm ± 3.9 and 242.3 Gy ± 63.6 (169.4 Gy ± 45.9 per whole liver volume), respectively. All patients remained at Child-Pugh Class A for 90 days. No patient experienced Grade 3‒4 hyperbilirubinemia or new ascites. One patient (lung dose, 27.8 Gy) developed radiation pneumonitis requiring transient steroid treatment. According to the posttreatment dosimetry, the tumorous and nontumorous liver absorbed doses were 418.8 Gy ± 227.4 and 69.0 Gy ± 32.1, respectively. The median DoR in a treated area and TTP were 22.0 and 17.1 months, respectively. The 5-year OS rate was 83.2%.
Conclusions: Ablative radioembolization of large HCC of ≥5 cm can be performed safely and effectively in patients with preserved liver function when FLR/NTLV exceeds 30%.
(Copyright © 2023 SIR. Published by Elsevier Inc. All rights reserved.)
المشرفين على المادة: 1K8M7UR6O1 (Yttrium-90)
0 (Yttrium Radioisotopes)
تواريخ الأحداث: Date Created: 20231022 Date Completed: 20240129 Latest Revision: 20240213
رمز التحديث: 20240213
DOI: 10.1016/j.jvir.2023.10.011
PMID: 37866475
قاعدة البيانات: MEDLINE
الوصف
تدمد:1535-7732
DOI:10.1016/j.jvir.2023.10.011